ID: MRFR/Pharma/4787-HCR | February 2021 | Region: Global | 100 pages
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on primary and secondary research.
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the overactive bladder treatment market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The overactive bladder treatment global market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and the overactive bladder in other disorders.
Geographically, the overactive bladder treatment global market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment global market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Global Overactive Bladder Treatment Market, by Pharmacotherapy
Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment
Global Overactive Bladder Treatment Market, by Disease
Global Overactive Bladder Treatment Market, by Region
|Market Size||Significant Value|
|CAGR||2018-2023: ~ 3.1%|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Pharmacotherapy, Non-Pharmacological Treatment, and Disease|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical, Allergan, Plc. , Mylan N.V. , Endo International Plc , Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Aurobindo Pharma Limited , Johnson & Johnson, Intas Pharmaceuticals Ltd. , Apotex Inc. , Macleods Pharmaceuticals Ltd. , Medtronic PLC, Cogentix Medical, Inc.|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Global overactive bladder treatment market is expected to grow at a CAGR of 3.1% by 2023.
The major key players of the overactive bladder treatment market are astellas pharma inc., pfizer, inc., teva pharmaceutical, allergan, plc. , mylan n.v. , endo international plc , hisamitsu pharmaceutical co., inc., sanofi s. A., aurobindo pharma limited , johnson & johnson, intas pharmaceuticals ltd. , apotex inc. , macleods pharmaceuticals ltd. , medtronic plc, cogentix medical, inc.
The types involved in the overactive bladder treatment market are favorable histology, unfavorable histology (anaplastic wilms tumor.
The major drivers of overactive bladder treatment market is rising geriatric population,